Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAVU solution is an experimental tissue preservation and transportation medium specifically developed for use in parathyroid allotransplantation. Developed by researchers at Şişli Hamidiye Etfal Training and Research Hospital, the solution is designed to optimize the viability of parathyroid cells and maintain the functional integrity of calcium-sensing receptors (CaSR) during the cold ischemia period. The name BAVU is an acronym derived from its primary components: Bicarbonate, Albumin, Vitamin E, and University of Wisconsin (UW) solution. It is primarily utilized in clinical research settings to improve the outcomes of parathyroid transplants in patients suffering from permanent hypoparathyroidism, often as a result of parathyroid hyperplasia or surgical complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BAVU solution.